HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has maintained a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) but has reduced the price target from $2 to $1.
November 14, 2023 | 6:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
SAB Biotherapeutics' price target has been lowered from $2 to $1 by HC Wainwright & Co., although the Buy rating is maintained.
The reduction in price target by a reputable analyst firm like HC Wainwright & Co. could lead to a negative short term sentiment among investors, potentially causing a decrease in SAB Biotherapeutics' stock price. However, the maintenance of a Buy rating suggests underlying confidence in the company's long-term prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100